LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Inicio・Lista de Acciones・Cassava Sciences Inc

Cassava Sciences Inc

Cerrado

SectorSanidad

2.93 -7.28

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.93

Máximo

3.19

Métricas clave
By Trading Economics
Ingresos	33M -11M
Ventas	840K 840K
BPA	-0.22
Margen de beneficios	-1,286.548
Empleados	30
EBITDA	35M -11M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+145.4% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-4.3M 142M
Apertura anterior	10.21
Cierre anterior	2.93

Noticias sobre sentimiento de mercado

By Acuity

13%

87%

17 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

1.56 / 1.7 Soporte y Resistencia

Cassava Sciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 dic 2025, 23:58 UTC

Adquisiciones, fusiones, absorciones

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 dic 2025, 23:56 UTC

Ganancias

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 dic 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 dic 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dic 2025, 21:50 UTC

Ganancias

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 dic 2025, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

11 dic 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 dic 2025, 23:37 UTC

Charlas de Mercado

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 dic 2025, 23:31 UTC

Ganancias

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dic 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 dic 2025, 22:35 UTC

Ganancias

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 dic 2025, 22:30 UTC

Ganancias

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 dic 2025, 22:09 UTC

Adquisiciones, fusiones, absorciones

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 dic 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 dic 2025, 22:05 UTC

Ganancias

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dic 2025, 21:51 UTC

Adquisiciones, fusiones, absorciones

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

11 dic 2025, 21:39 UTC

Ganancias

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 dic 2025, 21:39 UTC

Ganancias

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 dic 2025, 21:38 UTC

Ganancias

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 dic 2025, 21:37 UTC

Ganancias

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 dic 2025, 21:37 UTC

Charlas de Mercado

Broadcom Sees AI Revenue Doubling -- Market Talk

11 dic 2025, 21:34 UTC

Adquisiciones, fusiones, absorciones

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 dic 2025, 21:29 UTC

Adquisiciones, fusiones, absorciones

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 dic 2025, 21:28 UTC

Charlas de Mercado

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Dexus: Third Party Investors to Contribute Remainder

11 dic 2025, 21:27 UTC

Adquisiciones, fusiones, absorciones

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 dic 2025, 21:26 UTC

Adquisiciones, fusiones, absorciones

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 dic 2025, 21:25 UTC

Adquisiciones, fusiones, absorciones

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Comparación entre iguales

Cambio de precio

Cassava Sciences Inc previsión

Precio Objetivo

By TipRanks

145.4% repunte

Estimación a 12 Meses

Media 8 USD 145.4%

Máximo 8 USD

Mínimo 8 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cassava Sciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Cassava Sciences Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.56 / 1.7Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

17 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.